Urothelial carcinoma management in elderly or unfit patients

European Journal of Cancer, Supplement

Volumn 14, Issue 1, 2016, Pages 1-20

  Bellmunt, Joaquim ^a,b   Mottet, Nicolas ^c   De Santis, Maria ^d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITÉ JEAN MONNET   (France)

^d UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Chemotherapy; Cisplatin; Cisplatin 'unfit' patients; Upper tract urothelial carcinoma; Urothelial carcinoma; Vinflunine

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOVITINIB; DOXORUBICIN; EPIRUBICIN; EVEROLIMUS; GEFITINIB; GEMCITABINE; IFOSFAMIDE; LAPATINIB; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PEMETREXED; RAMUCIRUMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TOPOTECAN; VANDETANIB; VINBLASTINE; VINFLUNINE; VOLASERTIB;

ABDOMINAL PAIN; ANEMIA; ARTICLE; ASTHENIA; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CAUSE SPECIFIC SURVIVAL; CONSERVATIVE TREATMENT; CONSTIPATION; CYSTECTOMY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; GERIATRIC ASSESSMENT; HEALTH CARE QUALITY; HUMAN; LOCAL THERAPY; LYMPH NODE DISSECTION; MAINTENANCE THERAPY; NEPHROURETERECTOMY; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEPSIS; STOMATITIS; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT RESPONSE; VOMITING;

EID: 84962911677     PISSN: 13596349     EISSN: 18781217     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2016.01.001     Document Type: Article

References (146)

1. Globocan 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available from: (accessed April 2015). http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.
2. United Nations Department of Economic and Social Affairs Population Division. World population ageing: 1950-2050. Available from: (accessed April 2015). http://www.un.org/esa/population/publications/worldageing19502050/.
3. Gore J.L., Litwin M.S., Lai J., et al. Use of radical cystectomy for patients with invasive bladder cancer. J Natl Cancer Inst 2010, 102:802-811.
4. Gray P.J., Fedewa S.A., Shipley W.U., et al. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol 2013, 63:823-829.
5. Balar A., Bajorin D.F., Milowsky M.I. Management of invasive bladder cancer in patients who are not candidates for or decline cystectomy. Ther Adv Urol 2011, 3:107-117.
6. Pal S.K., Hurria A. Impact of age, sex, and comorbidity on cancer therapy and disease progression. J Clin Oncol 2010, 28:4086-4093.
7. Coresh J., Selvin E., Stevens L.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298:2038-2047.
8. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-S266.
9. Stern S., Behar S., Gottlieb S. Cardiology patient pages. Aging and diseases of the heart. Circulation 2003, 108:e99-e101.
10. Geriatric Urology 1 January 2014, Springer Science & Business. T.L. Griebling (Ed.).
11. Crome P., Lally F., Cherubini A., et al. Exclusion of older people from clinical trials: professional views from nine European countries participating in the PREDICT study. Drugs Aging 2011, 28:667-677.
12. Pallis A.G., Ring A., Fortpied C., et al. EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors. Ann Oncol 2011, 22:1922-1926.
13. Hutchins L.F., Unger J.M., Crowley J.J., Coltman C.A., Albain K.S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999, 341:2061-2067.
14. Galsky M.D., Krege S., Lin C.C., et al. Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer. Urol Oncol 2014, 32:30.e15-30.e21.
15. Decoster L., Van Puyvelde K., Mohile S., et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. Ann Oncol 2015, 26:288-300.
16. Wildiers H., Heeren P., Puts M., et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 2014, 32:2595-2603.
17. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Older Adult Oncology Version 2. 2015. Available from: - age (accessed 9 November 2015). http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
18. Wedding U., Kodding D., Pientka L., Steinmetz H.T., Schmitz S. Physicians' judgement and comprehensive geriatric assessment (CGA) select different patients as fit for chemotherapy. Crit Rev Oncol Hematol 2007, 64:1-9.
19. Bellera C.A., Rainfray M., Mathoulin-Pélissier S., et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol 2012, 23:2166-2172.
20. Balducci L., Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000, 5:224-237.
21. Guidelines on muscle-invasive and metastatic bladder cancer 2015, European Association of Urology.
22. Fleshner N.E., Herr H.W., Stewart A.K., Murphy G.P., Mettlin C., Menck H.R. The National Cancer Data Base report on bladder carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1996, 78:1505-1513.
23. Nielsen M.E., Shariat S.F., Karakiewicz P.I., et al. Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol 2007, 51:699-706. discussion-8.
24. Snyder C., Harlan L., Knopf K., Potosky A., Kaplan R. Patterns of care for the treatment of bladder cancer. J Urol 2003, 169:1697-1701.
25. Goossens-Laan C.A., Leliveld A.M., Verhoeven R.H., et al. Effects of age and comorbidity on treatment and survival of patients with muscle-invasive bladder cancer. Int J Cancer 2014, 135:905-912.
26. Horovitz D., Turker P., Bostrom P.J., et al. Does patient age affect survival after radical cystectomy?. BJU Int 2012, 110:E486-E493.
27. Chromecki T.F., Mauermann J., Cha E.K., et al. Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy. World J Urol 2012, 30:753-759.
28. Zakaria A.S., Santos F., Dragomir A., Tanguay S., Kassouf W., Aprikian A.G. Postoperative mortality and complications after radical cystectomy for bladder cancer in Quebec: a population-based analysis during the years 2000-2009. Can Urol Assoc J 2014, 8:259-267.
29. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005, 48:202-205. discussion 5-6.
30. Griffiths G., Hall R., Sylvester R., Raghavan D., Parmar M.K. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011, 29:2171-2177.
31. Leow J.J., Martin-Doyle W., Rajagopal P.S., et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol 2014, 66:42-54.
32. Abdollah F., Sun M., Shariat S.F., et al. The importance of pelvic lymph node dissection in the elderly population: implications for interpreting the 2010 National Comprehensive Cancer Network practice guidelines for bladder cancer treatment. J Urol 2011, 185:2078-2084.
33. Sternberg C.N., Skoneczna I., Kerst J.M., et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol 2015, 16:76-86.
34. Coppin C.M., Gospodarowicz M.K., James K., et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996, 14:2901-2907.
35. Hoskin P.J., Rojas A.M., Bentzen S.M., Saunders M.I. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol 2010, 28:4912-4918.
36. James N.D., Hussain S.A., Hall E., et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012, 366:1477-1488.
37. Mak R.H., Hunt D., Shipley W.U., et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 2014, 32:3801-3809.
38. Rene N.J., Cury F.B., Souhami L. Conservative treatment of invasive bladder cancer. Curr Oncol 2009, 16:36-47.
39. Ploussard G., Daneshmand S., Efstathiou J.A., et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol 2014, 66:120-137.
40. Chamie K., Hu B., Devere White R.W., Ellison L.M. Cystectomy in the elderly: does the survival benefit in younger patients translate to the octogenarians?. BJU Int 2008, 102:284-290.
41. Solsona E., Iborra I., Ricos J.V., Monros J.L., Casanova J., Calabuig C. Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: long-term followup of a prospective study. J Urol 1998, 159:95-98. discussion 8-9.
42. Herr H.W. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 2001, 19:89-93.
43. Ma B., Li H., Zhang C., et al. Lymphovascular invasion, ureteral reimplantation and prior history of urothelial carcinoma are associated with poor prognosis after partial cystectomy for muscle-invasive bladder cancer with negative pelvic lymph nodes. Eur J Surg Oncol 2013, 39:1150-1156.
44. Holzbeierlein J.M., Lopez-Corona E., Bochner B.H., et al. Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. J Urol 2004, 172:878-881.
45. Malkowicz S.B., van Poppel H., Mickisch G., et al. Muscle-invasive urothelial carcinoma of the bladder. Urology 2007, 69:3-16.
46. Dandekar N.P., Tongaonkar H.B., Dalal A.V., Kulkarni J.N., Kamat M.R. Partial cystectomy for invasive bladder cancer. J Surg Oncol 1995, 60:24-29.
47. Knoedler J., Frank I. Organ-sparing surgery in urology: partial cystectomy. Curr Opin Urol 2015, 25:111-115.
48. Turgeon G.A., Souhami L., Cury F.L., et al. Hypofractionated intensity modulated radiation therapy in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer. Int J Radiat Oncol Biol Phys 2014, 88:326-331.
49. Lacarriere E., Smaali C., Benyoucef A., Pfister C., Grise P. The efficacy of hemostatic radiotherapy for bladder cancer-related hematuria in patients unfit for surgery. Int Braz J Urol 2013, 39:808-816.
50. Kouloulias V., Tolia M., Kolliarakis N., Siatelis A., Kelekis N. Evaluation of acute toxicity and symptoms palliation in a hypofractionated weekly schedule of external radiotherapy for elderly patients with muscular invasive bladder cancer. Int Braz J Urol 2013, 39:77-82.
51. Zygogianni A., Kouloulias V., Armpilia C., et al. A weekly hypofractionated radiotherapeutic schedule for bladder carcinoma in elderly patients: local response, acute and late toxicity, dosimetric parameters and pain relief. J BUON 2013, 18:407-412.
52. von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000, 18:3068-3077.
53. von der Maase H., Sengelov L., Roberts J.T., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005, 23:4602-4608.
54. Sternberg C.N., de Mulder P., Schornagel J.H., et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006, 42:50-54.
55. Galsky M.D., Chen G.J., Oh W.K., et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol 2012, 23:406-410.
56. Petrioli R., Frediani B., Manganelli A., et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer 1996, 77:344-351.
57. Bellmunt J., Ribas A., Eres N., et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 1997, 80:1966-1972.
58. Dogliotti L., Carteni G., Siena S., et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 2007, 52:134-141.
59. Sonpavde G., Watson D., Tourtellott M., et al. Frequency of cisplatin administration in patients presenting with advanced urothelial carcinoma in the community. J Clin Oncol 2012, 30. abstr 285.
60. Galsky M.D., Chowdhury S., Bellmunt J., et al. Treatment patterns and outcomes in "real world" patients (pts) with metastatic urothelial cancer (UC). J Clin Oncol 2013, 31. abstr 4525.
61. Bamias A., Peroukidis S., Stamatopoulou S., et al. Utilization of systemic chemotherapy in advanced urothelial cancer: a retrospective collaborative study by the Hellenic Genitourinary Cancer Group (HGUCG). Clin Genitourin Cancer 2015, (in press).
62. Dash A., Galsky M.D., Vickers A.J., et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 2006, 107:506-513.
63. Nogue-Aliguer M., Carles J., Arrivi A., et al. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer 2003, 97:2180-2186.
64. De Santis M., Bachner M. New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder. Curr Opin Urol 2007, 17:363-368.
65. Galsky M.D., Hahn N.M., Rosenberg J., et al. Treatment of patients with metastatic urothelial cancer "unfit" for cisplatin-based chemotherapy. J Clin Oncol 2011, 29:2432-2438.
66. Witjes J.A., Comperat E., Cowan N.C., et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 2014, 65:778-792.
67. Yamamoto N., Tamura T., Maeda M., et al. The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function. Cancer Chemother Pharmacol 1995, 36:102-106.
68. Raj G.V., Iasonos A., Herr H., Donat S.M. Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer. J Clin Oncol 2006, 24:3095-3100.
69. de Lusignan S., Chan T., Gallagher H., et al. Chronic kidney disease (CKD) management in southeast England: a preliminary cross-sectional report from the QICKD - Quality Improvement in Chronic Kidney Disease study. Prim Care Cardiovasc J 2009, 2:33-39.
70. Grisold W., Cavaletti G., Windebank A.J. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol 2012, 14(Suppl. 4):iv45-iv54.
71. Herr H.W. Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 2008, 54:126-132.
72. Sternberg C.N., Pansadoro V., Calabro F., et al. Can patient selection for bladder preservation be based on response to chemotherapy?. Cancer 2003, 97:1644-1652.
73. Meyer A., Ghandour R., Bergman A., et al. The natural history of clinically complete responders to neoadjuvant chemotherapy for urothelial carcinoma of the bladder. J Urol 2014, 192:696-701.
74. Carles J., Nogue M., Domenech M., et al. Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function. Oncology 2000, 59:24-27.
75. Bellmunt J., de Wit R., Albanell J., Baselga J. A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. Eur J Cancer 2001, 37:2212-2215.
76. Linardou H., Aravantinos G., Efstathiou E., et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: phase II study of the Hellenic Co-operative Oncology Group. Urology 2004, 64:479-484.
77. Bamias A., Lainakis G., Kastritis E., et al. Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: report of efficacy, quality of life and geriatric assessment. Oncology 2007, 73:290-297.
78. De Santis M., Bellmunt J., Mead G., et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012, 30:191-199.
79. Vaughn D.J., Manola J., Dreicer R., See W., Levitt R., Wilding G. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group. Cancer 2002, 95:1022-1027.
80. Calabro F., Lorusso V., Rosati G., et al. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer 2009, 115:2652-2659.
81. Ricci S., Galli L., Chioni A., et al. Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens. Cancer 2002, 95:1444-1450.
82. Culine S., Flechon A., Guillot A., et al. Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French Genitourinary Tumor Group (GETUG V01). Eur Urol 2011, 60:1251-1257.
83. Galsky M.D., Iasonos A., Mironov S., Scattergood J., Boyle M.G., Bajorin D.F. Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. Cancer 2007, 109:549-555.
84. Balar A.V., Apolo A.B., Ostrovnaya I., et al. Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. J Clin Oncol 2013, 31:724-730.
85. Bellmunt J., Gonzalez-Larriba J.L., Prior C., et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol 2011, 22:2646-2653.
86. De Santis M., Bellmunt J., Mead G., et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II-results of EORTC study 30986. J Clin Oncol 2009, 27:5634-5639.
87. De Santis M., Wiechno P.J., Lucas C., et al. Mature survival (OS) data of a randomised international phase II trial (JASINT1): vinflunine (VFL)-gemcitabine (GEM) vs. VFL-CBDCA in CDDP-unfit patients (Pts) with advanced urothelial carcinoma. Ann Oncol 2014, 25:iv280-iv304. (812PD).
88. Ko Y.J., Canil C.M., Mukherjee S.D., et al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncol 2013, 14:769-776.
89. Yafi F.A., North S., Kassouf W. First- and second-line therapy for metastatic urothelial carcinoma of the bladder. Curr Oncol 2011, 18:e25-e34.
90. von der Maase H. Gemcitabine in transitional cell carcinoma of the urothelium. Expert Rev Anticancer Ther 2003, 3:11-19.
91. Albers P., Park S.I., Niegisch G., et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol 2011, 22:288-294.
92. Sternberg C.N., Vogelzang N.J. Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. Crit Rev Oncol Hematol 2003, 46(Suppl):S105-S115.
93. Kaufmann D.S., Carducci M.A., Kuzel T., et al. Gemcitabine (G) and paclitaxel (P) every two weeks (GP2w): a completed multicenter phase II trial in locally advanced or metastatic urothelial cancer (UC). Proc Am Soc Clin Oncol 2002, 21(1):192a. Abstr 767.
94. Wong Y., Litwin S., Plimack E.R., et al. Effect of EGFR inhibition with cetuximab on the efficacy of paclitaxel in previously treated metastatic urothelial cancer. J Clin Oncol 2011, 29. abstr 243.
95. Choueiri T.K., Ross R.W., Jacobus S., et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol 2012, 30:507-512.
96. Petrylak D.P., Tagawa S.T., Kohli M., et al. Interim results of a randomized phase 2 study of docetaxel with ramucirumab versus docetaxel in second-line advanced or metastatic urothelial carcinoma. J Clin Oncol 2015, 33. abstr 295.
97. Srinivas S., Narayanan S., Harshman L.C., et al. Phase II study of pazopanib with weekly paclitaxel in refractory urothelial cancer. J Clin Oncol 2015, 33. abstr 294.
98. Bellmunt J., Fougeray R., Rosenberg J.E., et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol 2013, 24:1466-1472.
99. Bellmunt J., Choueiri T.K., Fougeray R., et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010, 28:1850-1855.
100. Sonpavde G., Pond G.R., Fougeray R., et al. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol 2013, 63:717-723.
101. Serrate C., Pouessel D., Gauthier H., le Maignan C., Teixeira L., Culine S. Vinflunine for the treatment of metastatic transitional cell carcinoma: recent evidence from clinical trials and observational studies. Clinic Investig 2014, 4:305-311.
102. Hussain S.A., Ansari J., Huddart R.A., et al. VICTOR: vinflunine (Vin) in advanced metastatic transitional cell carcinoma of the urothelium (TCCU)-a retrospective analysis of use of Vin in multicenter, real life setting as second-line chemotherapy (ChT) through free-of charge-programme (FOCP) for patients (pts) in the UK. J Clin Oncol 2015, 33. abstr 352.
103. Castellano D., Puente J., de Velasco G., et al. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice. BMC Cancer 2014, 14:779.
104. Pistamaltzian N., Tzannis K., Pissanidou V., et al. Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer Group. Anticancer Drugs 2016, 27:48-53.
105. Aapro M.S., Bohlius J., Cameron D.A., et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011, 47:8-32.
106. Isambert N., Delord J.P., Tourani J.M., et al. How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I study. Br J Clin Pharmacol 2014, 77:498-508.
107. Tourani J.M., Mourey L., Servent V., et al. Influence of age on the pharmacokinetics of i.v. vinflunine: results of a phase I trial in elderly cancer patients. Journal of Geriatric Oncology 2012, 3:41-48.
108. Guidelines on urothelial carcinomas of the upper urinary tract 2015, European Association of Urology.
109. Capitanio U., Shariat S.F., Isbarn H., et al. Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur Urol 2009, 56:1-9.
110. Lughezzani G., Sun M., Perrotte P., et al. Should bladder cuff excision remain the standard of care at nephroureterectomy in patients with urothelial carcinoma of the renal pelvis? A population-based study. Eur Urol 2010, 57:956-962.
111. Xylinas E., Rink M., Cha E.K., et al. Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol 2014, 65:210-217.
112. Margulis V., Shariat S.F., Matin S.F., et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009, 115:1224-1233.
113. Ito A., Shintaku I., Satoh M., et al. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. J Clin Oncol 2013, 31:1422-1427.
114. O'Brien T., Ray E., Singh R., Coker B., Beard R. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol 2011, 60:703-710.
115. Knowles M.A., Hurst C.D. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 2015, 15:25-41.
116. Martin-Doyle W., Leow J.J., Orsola A., Chang S.L., Bellmunt J. Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients. J Clin Oncol 2015, 33:643-650.
117. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 2005;48:189-199; discussion 99-201.
118. Svatek R.S., Shariat S.F., Lasky R.E., et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res 2010, 16:4461-4467.
119. Van Allen E.M., Mouw K.W., Kim P., et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 2014, 4:1140-1153.
120. Groenendijk F.H., de Jong J., Fransen van de Putte E.E., et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol 2015, 69:384-388.
121. Dinney C.P., Hansel D., McConkey D., et al. Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum. Urol Oncol 2014, 32:1108-1115.
122. Choudhury A., Nelson L.D., Teo M.T., et al. MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res 2010, 70:7017-7026.
123. Lautenschlaeger T., George A., Klimowicz A.C., et al. Bladder preservation therapy for muscle-invading bladder cancers on Radiation Therapy Oncology Group trials 8802, 8903, 9506, and 9706: vascular endothelial growth factor B overexpression predicts for increased distant metastasis and shorter survival. Oncologist 2013, 18:685-686.
124. Bellmunt J., Selvarajah S., Rodig S., et al. Identification of ALK gene alterations in urothelial carcinoma. PLoS One 2014, 9:e103325.
125. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014, 507:315-322.
126. Iyer G., Hanrahan A.J., Milowsky M.I., et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012, 338:221.
127. Sequist L.V., Cassier P., Varga A., et al. Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors 2014, American Association for Cancer Research, Philadelphia, abstr. CT326.
128. Bahleda R., Dienstmann R., Adamo B., et al. Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors. J Clin Oncol 2014, 32. abstr 2501.
129. Bellmunt J., Mullane S.A., Werner L., et al. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol 2015, 26:812-817.
130. Powles T., Eder J.P., Fine G.D., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014, 515:558-562.
131. Kim J.W., Bellmunt J., Powles T., et al. Clinical activity, safety, and biomarkers of MPDL3280A in metastatic urothelial bladder cancer: additional analysis from phase IA study. J Clin Oncol 2015, 33. abstr 297.
132. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
133. McConkey D.J., Choi W., Dinney C.P. New insights into subtypes of invasive bladder cancer: considerations of the clinician. Eur Urol 2014, 66:609-610.
134. Siefker-Radtke A.O., Choi W., Porten S.P., et al. The basal subtype to predict clinical benefit from neoadjuvant chemotherapy: final results from a phase II clinical trial of DDMVAC plus bevacizumab. J Clin Oncol 2015, 33. abstr 291.
135. Bellmunt J., Orsola A., Leow J.J., Wiegel T., De Santis M., Horwich A. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014, 25(Suppl. 3):iii40-iii48.
136. Bennouna J., Delord J.P., Campone M., Nguyen L. Vinflunine: a new microtubule inhibitor agent. Clin Cancer Res 2008, 14:1625-1632.
137. Aparicio L.A., Castosa R., Haz-Conde M., et al. Role of the microtubule-targeting drug vinflunine on cell-cell adhesions in bladder epithelial tumour cells. BMC Cancer 2014, 14:507.
138. Pourroy B., Honore S., Pasquier E., et al. Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells. Cancer Res 2006, 66:3256-3263.
139. Kruczynski A., Poli M., Dossi R., et al. Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur J Cancer 2006, 42:2821-2832.
140. Aparicio L.M., Pulido E.G., Gallego G.A. Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity. Anticancer Drugs 2012, 23:1-11.
141. Ciuleanu T., Brodowicz T., Zielinski C., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432-1440.
142. Cappuzzo F., Ciuleanu T., Stelmakh L., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529.
143. Paz-Ares L.G., de Marinis F., Dediu M., et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013, 31:2895-2902.
144. Grivas P.D., Daignault S., Tagawa S.T., et al. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer 2014, 120:692-701.
145. Powles T., Huddart R.A., Elliott T., et al. A phase II/III, double-blind, randomized trial comparing maintenance lapatinib versus placebo after first line chemotherapy in HER1/2 positive metastatic bladder cancer patients. J Clin Oncol 2015, 33. abstr 4505.
146. Bellmunt J., Perez Valderrama B., Font A., et al. Maintenance vinflunine post cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC): preliminary analysis of a randomized placebo controlled phase II trial (MAJA trial)-SOGUG 2011-02. J Clin Oncol 2015, 33. Abstract 4529.